The leading index fund of biotechnology stocks (XBI) has lost more than 60% of its value from its peak in February of 2021. This has negatively impacted investor returns and stalled investment ...

"Instead of being beholden to the binary nature of biotech events, investing in a broader pool of biotech firms helps hedge risk for negative events while still having significant exposure to long ...

According to BioSpace, investment in biopharma (biotech + pharmaceutical companies) in 2024 increased by 11% from $23.3 billion to $26 billion. Furthermore, HSBC’s 2024 annual venture healthcare ...